Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Policy / Regulatory

China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings

Fineline Cube Sep 11, 2025

The Center for Drug Evaluation (CDE), part of China’s National Medical Products Administration (NMPA), published...

Policy / Regulatory

China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach

Fineline Cube Sep 11, 2025

The State Council released the Implementation Plan for the Healthcare Foundation Strengthening Project, setting a...

Company Drug

TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination

Fineline Cube Sep 11, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced that the China National Medical Products Administration has...

Company Deals

Innovent Biologics & Cowell Health Forge Strategic Alliance to Boost Drug Access

Fineline Cube Sep 11, 2025

Innovent Biologics Inc. (HKG: 1801) announced a strategic cooperation agreement with Cowell Health. The partnership is...

Company Drug

Taiji Group Secures NMPA Approval to Begin Clinical Trials of Semaglutide Biosimilar

Fineline Cube Sep 11, 2025

China‑based Chongqing Taiji Industry (Group) Co., Ltd. (Taiji Group, SHA: 600129) announced that its semaglutide...

Company Drug

Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors

Fineline Cube Sep 11, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation

Fineline Cube Sep 10, 2025

China‑based Qilu Pharmaceutical and the Foundation for the Development of Science and Technology in China (FDSTC),...

Company Deals

Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development

Fineline Cube Sep 10, 2025

China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...

Company Deals Medical Device

Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis

Fineline Cube Sep 10, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced that its operating subsidiary,...

Company Drug Medical Device

Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer

Fineline Cube Sep 10, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug...

Others

China’s 11th National Drug VBP Draft Unveils Major Pricing & Competition Reforms

Fineline Cube Sep 10, 2025

The second‑draft rules for China’s 11th round of national centralized drug procurement (VBP 11th) have...

Company Deals Drug

Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib

Fineline Cube Sep 10, 2025

China‑listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell...

Company

Novo Nordisk Launches Company‑Wide Transformation to Drive Diabetes and Obesity Growth

Fineline Cube Sep 10, 2025

Danish diabetes and obesity leader Novo Nordisk A/S (NYSE: NVO) announced a sweeping organisational overhaul...

Company Deals

IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance

Fineline Cube Sep 10, 2025

China‑based IASO Biotherapeutics and Shenzhen Cellbri Bio‑Innovation Technology Co., Ltd. announced a global strategic cooperation...

Company Drug

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer

Fineline Cube Sep 10, 2025

China‑based Qilu Pharmaceutical Co., Ltd. announced that it has opened enrollment for its first‑in‑class QLS31905...

Company Drug

Novartis Expands Iptacopan Approval to IgA Nephropathy in China

Fineline Cube Sep 10, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first‑in‑class oral inhibitor Iptacopan (Fabhalta) has...

Company Drug

Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection

Fineline Cube Sep 9, 2025

China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND)...

Company Drug

Simcere Secures NMPA Approval for CDH17‑Targeting ADC SIM0609 in Advanced Solid Tumors

Fineline Cube Sep 9, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its internally developed SIM0609, a CDH17 antibody‑drug...

Company Medical Device

DaAn Gene Secures NMPA Approval for First HIVDNA Diagnostic Kit

Fineline Cube Sep 9, 2025

China‑based DaAn Gene Co., Ltd. (SHE: 002030), a research arm of Sun Yat‑sen University, announced that...

Policy / Regulatory

NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight

Fineline Cube Sep 9, 2025

The National Medical Products Administration (NMPA) issued a draft of its Compliance Guidelines for Online...

Posts pagination

1 … 157 158 159 … 718

Recent updates

  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
  • NMPA Accepts Yantai Dongcheng’s Marketing Application for Bemiparin Sodium Injection – Potential First Generic of Ultra‑Low Molecular Weight Heparin in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Company Deals

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.